A Billion Dollar Opportunity Ahead?
One Biotech Company Has Begun to Capitvate Investors & A New CEO At The Helm Could Be Presenting Near Term Opportunity!
Biogen Increases Sample Size for Alzheimer’s Phase 3; Stock Takes a Dip
Biogen has decided to add 510 patients its upcoming phase 3 aducanumab trails because they didn’t expect to have so much variability in a sample size re-estimation. The midstudy changes to its Alzheimer’s program had scared its investors.